Mazdutide for type 2 diabetes with fatty liver after semaglutide
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether mazdutide, a new medicine, can improve blood sugar and reduce liver fat in people with type 2 diabetes and moderate-to-severe fatty liver who are already taking semaglutide (a weekly injection). It aims to find a more effective treatment for these combined conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have type 2 diabetes and have been taking semaglutide 1.0 mg weekly for at least 4 months.
- You must have moderate-to-severe fatty liver, confirmed by a special scan (elastography and MRI).
- Your blood sugar control must be good (HbA1c less than 7%).
- Your body mass index (BMI) must be 24 or higher.
- You must not have other liver diseases (like from alcohol or viruses), or a history of pancreatitis, certain thyroid tumors, or multiple endocrine neoplasia.
- You must not be pregnant, planning pregnancy, or breastfeeding, and you must not have any metal implants or other reasons that prevent an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
This trial tests a medicine called semaglutide (often used for diabetes) to see if it helps people in Bangladesh who are overweight or obese lose weight. The study will check if the medicine is safe and effective for both people with and without type 2 diabetes.
This trial tests a new medicine called mazdutide to see if it can help people with type 2 diabetes achieve remission (return to normal blood sugar levels without needing medicine). It's a placebo-controlled study, meaning some participants will get the real drug and others will get a fake one, to compare results. You must be within 5 years of diagnosis and have a BMI over 24.
This study tests whether adding a new medicine, CS0159, to a standard diabetes drug (semaglutide) can improve liver health and blood sugar in people with fatty liver disease, obesity, and type 2 diabetes. It may help reduce liver fat and support weight loss.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.